enGene to Present Details of its Pivotal Phase 1/2 LEGEND Study of EG-70 in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ at the American Urology Association 2024 Annual Meeting [Yahoo! Finance]
enGene to Present Details of its Pivotal Phase 1/2 LEGEND Study of EG-70 in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ at the American Urology Association 2024 Annual Meeting
enGene Holdings Inc. (NASDAQ: ENGN) is now covered by analysts at Wells Fargo & Company. They set an "overweight" rating and a $30.00 price target on the stock.
enGene Holdings Inc. (NASDAQ: ENGN) is now covered by analysts at Guggenheim. They set a "buy" rating and a $34.00 price target on the stock.
engender Announces Hiring of Dr. Raja Ruth as Senior Vice President, Urologic Oncology and Clinical Development